MedTrace Logo

Lidocaine Supplement for Minimal Invasive Parathyroid Surgery

NCT00528502 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2012-12-07

No results posted yet for this study

Summary

Primary Objective:

1\. To determine if the application of lidocaine to the airway will obtund or abolish the laryngeal reflexes. This in turn will lead to a quiescent controlled surgical field.

Conditions

  • Parathyroid Disease

Interventions

DRUG

Lidocaine

Lidocaine is misted into the air that you breathe during the surgery.

DRUG

Saline

Saline is misted into the air that you breathe during the surgery.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Spencer Kee, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-01-31
Completion
2008-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00528502 on ClinicalTrials.gov